Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.

Bloemendaal FM, Levin AD, Wildenberg ME, Koelink PJ, McRae BL, Salfeld J, Lum J, van der Neut Kolfschoten M, Claassens JW, Visser R, Bentlage A, D'Haens GRAM, Verbeek JS, Vidarsson G, van den Brink GR.

Gastroenterology. 2017 Nov;153(5):1351-1362.e4. doi: 10.1053/j.gastro.2017.07.021. Epub 2017 Jul 27.

PMID:
28756234
2.

Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease.

McRae BL, Levin AD, Wildenberg ME, Koelink PJ, Bousquet P, Mikaelian I, Sterman AS, Bryant S, D'Haens G, Kamath R, Salfeld J, van den Brink GR.

J Crohns Colitis. 2016 Jan;10(1):69-76. doi: 10.1093/ecco-jcc/jjv179. Epub 2015 Oct 1.

PMID:
26429698
3.

CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.

Stuhlmüller B, Häupl T, Hernandez MM, Grützkau A, Kuban RJ, Tandon N, Voss JW, Salfeld J, Kinne RW, Burmester GR.

Clin Pharmacol Ther. 2010 Mar;87(3):311-21. doi: 10.1038/clpt.2009.244. Epub 2009 Dec 23.

PMID:
20032971
4.

Expression of antibodies using single-open reading frame vector design and polyprotein processing from mammalian cells.

Kunes YZ, Gion WR, Fung E, Salfeld JG, Zhu RR, Sakorafas P, Carson GR.

Biotechnol Prog. 2009 May-Jun;25(3):735-44. doi: 10.1002/btpr.182.

PMID:
19363814
5.

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.

Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH.

Clin Immunol. 2009 May;131(2):308-16. doi: 10.1016/j.clim.2009.01.002. Epub 2009 Feb 1.

PMID:
19188093
6.

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.

Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP.

Pharmacol Ther. 2008 Feb;117(2):244-79. Epub 2007 Oct 26. Review.

PMID:
18155297
7.

Isotype selection in antibody engineering.

Salfeld JG.

Nat Biotechnol. 2007 Dec;25(12):1369-72. Review. No abstract available.

PMID:
18066027
8.

The biotechnology era: has the promise been fulfilled?

Salfeld JG.

Expert Opin Drug Discov. 2007 Dec;2(12):1549-53. doi: 10.1517/17460441.2.12.1549.

PMID:
23488899
9.

Overview on the use of therapeutic antibodies in drug discovery.

Roguska M, Kaymakcalan Z, Salfeld J.

Curr Protoc Pharmacol. 2005 Jan 1;Chapter 9:Unit 9.7. doi: 10.1002/0471141755.ph0907s27.

PMID:
22294129
10.

Anti-interleukin-12 antibody for active Crohn's disease.

Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W; Anti-IL-12 Crohn's Disease Study Group.

N Engl J Med. 2004 Nov 11;351(20):2069-79. Erratum in: N Engl J Med. 2005 Mar 24;352(12):1276. Yang, Zhiqiong [added].

11.

Use of new biotechnology to design rational drugs against newly defined targets.

Salfeld JG.

Best Pract Res Clin Rheumatol. 2004 Feb;18(1):81-95. Review.

PMID:
15123039
12.

Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock.

Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskind M, Rodman L, Salfeld J, et al.

Cell. 1995 Feb 10;80(3):401-11.

13.

A tripartite HIV-1 tat-env-rev fusion protein.

Salfeld J, Göttlinger HG, Sia RA, Park RE, Sodroski JG, Haseltine WA.

EMBO J. 1990 Mar;9(3):965-70.

14.

Expression and structural and functional properties of human ferritin L-chain from Escherichia coli.

Levi S, Salfeld J, Franceschinelli F, Cozzi A, Dorner MH, Arosio P.

Biochemistry. 1989 Jun 13;28(12):5179-84.

PMID:
2669970
15.
16.

Detection of hepatitis B virus core gene products in sera and liver of HBV-infected individuals.

Theilmann L, Pfaff E, Kommerell B, Gmelin K, Schaller H, Salfeld J.

J Hepatol. 1989 Jan;8(1):77-85.

PMID:
2921507
17.
19.

Expression of the hepatitis B virus core gene in vitro and in vivo.

Weimer T, Salfeld J, Will H.

J Virol. 1987 Oct;61(10):3109-13.

20.

Synthesis of the X-protein of hepatitis B virus in vitro and detection of anti-X antibodies in human sera.

Pfaff E, Salfeld J, Gmelin K, Schaller H, Theilmann L.

Virology. 1987 Jun;158(2):456-60.

PMID:
3035793
21.

Pre-S1 proteins in sera of patients positive for HBsAg and antibodies to hepatitis delta virus.

Theilmann L, Gmelin K, Tapalaga D, Salfeld J, Kommerell B, Pfaff E.

Hepatogastroenterology. 1987 Apr;34(2):53-5.

PMID:
3596456
22.

Production of hepatitis B virus in vitro by transient expression of cloned HBV DNA in a hepatoma cell line.

Chang CM, Jeng KS, Hu CP, Lo SJ, Su TS, Ting LP, Chou CK, Han SH, Pfaff E, Salfeld J, et al.

EMBO J. 1987 Mar;6(3):675-80.

23.

The influence of purified recombinant human heavy-subunit and light-subunit ferritins on colony formation in vitro by granulocyte-macrophage and erythroid progenitor cells.

Broxmeyer HE, Lu L, Bicknell DC, Williams DE, Cooper S, Levi S, Salfeld J, Arosio P.

Blood. 1986 Dec;68(6):1257-63.

PMID:
3490884
24.

Detection of pre-S1 proteins in serum and liver of HBsAg-positive patients: a new marker for hepatitis B virus infection.

Theilmann L, Klinkert MQ, Gmelin K, Salfeld J, Schaller H, Pfaff E.

Hepatology. 1986 Mar-Apr;6(2):186-90.

PMID:
3957230
25.

Putative reverse transcriptase intermediates of human hepatitis B virus in primary liver carcinomas.

Will H, Salfeld J, Pfaff E, Manso C, Theilmann L, Schaler H.

Science. 1986 Feb 7;231(4738):594-6.

PMID:
2418501
26.

Structure of human ferritin light subunit messenger RNA: comparison with heavy subunit message and functional implications.

Dörner MH, Salfeld J, Will H, Leibold EA, Vass JK, Munro HN.

Proc Natl Acad Sci U S A. 1985 May;82(10):3139-43.

Supplemental Content

Loading ...
Support Center